CDK1 and scleroderma: In conclusion, our study provides new evidence that esomeprazole exerts anti-proliferative effects on scleroderma fibroblasts by inducing cell cycle arrest through p21 upregulation and CDK1 and CDK2 downregulation (Figure 5).